BMY - Bristol-Myers in charts: Revenue from Eliquis rises while Opdivo drops in Q1
2024-04-25 07:44:29 ET
More on Bristol-Myers Squibb Company
- Is Bristol Myers Squibb A Buy At These Bottom Levels?
- Bristol-Myers Squibb: Market Pessimism Won't Last Forever
- Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
- Bristol-Myers Squibb Company Non-GAAP EPS of -$4.40 beats by $0.02, revenue of $11.78B beats by $330M
- Bristol-Myers Earnings Preview: Major near-term headwinds invites worries about Q1 results